요실금용 기기 시장 : 디바이스 유형, 소재, 기술, 성별, 형태, 연령층, 용도, 최종사용자, 유통 채널별 - 시장 예측(2026-2032년)

The Urinary Incontinence Device Market is projected to grow by USD 10.25 billion at a CAGR of 7.78% by 2032.

Urinary Incontinence Device Market Overview

Urinary incontinence devices are becoming a strategic category within urology, urogynecology, elder care, and home healthcare as health systems respond to aging populations, higher diagnosis rates, and rising demand for discreet, evidence-based continence management. The market includes external urine management systems, catheters, pessaries, urethral inserts, male slings, artificial urinary sphincters, electrical stimulation systems, neuromodulation technologies, absorbent-adjacent device platforms, and digital monitoring tools used across stress, urge, overflow, functional, and mixed urinary incontinence.

Verified public-health evidence consistently shows that urinary incontinence is common yet underreported, especially among women, older adults, people after childbirth, patients with neurologic conditions, and men following prostate procedures. This creates a significant care gap, as many patients first rely on lifestyle changes or absorbent products before receiving device-based interventions. For manufacturers, providers, and investors, the opportunity is to improve clinical outcomes while reducing skin complications, infections, caregiver burden, fall risk, and avoidable institutional care costs.

Transformative Shifts in the Continence Care Landscape

The landscape is shifting from episodic symptom management toward integrated continence care pathways. Hospitals and outpatient urology clinics are adopting minimally invasive and reversible options, while long-term care and home-care settings are prioritizing external collection systems and monitoring technologies that reduce caregiver workload and support infection-control protocols. This transition aligns with broader healthcare trends, including shorter hospital stays, more home-based recovery, and increased attention to patient-reported quality-of-life outcomes.

Product innovation is also changing competitive dynamics. Wearable designs, female external urine collection devices, antimicrobial and closed-system catheter improvements, rechargeable neuromodulation platforms, and patient-friendly app connectivity are raising expectations for comfort, discretion, and adherence. At the same time, regulators and payers are scrutinizing clinical evidence, real-world safety, reimbursement coding, cybersecurity, and total cost of care, making robust outcomes data a key differentiator.

Cumulative Impact of Artificial Intelligence on Device Innovation

Artificial intelligence is moving urinary incontinence devices from passive support toward predictive, personalized care. AI-enabled bladder diaries, sensor-based voiding pattern analysis, and connected pelvic-floor therapy tools can help clinicians identify symptom triggers, optimize treatment timing, and monitor adherence between visits. In long-term care, AI-supported alerts may help reduce missed toileting opportunities and improve workflow efficiency when deployed with appropriate clinical oversight and privacy safeguards.

The cumulative impact is strongest where AI complements clinical decision-making rather than replacing it. Algorithms trained on validated and representative data can support risk stratification for urinary tract infection, catheter-associated complications, nocturia-related falls, and therapy nonresponse. However, industry leaders must address data quality, interoperability, cybersecurity, algorithmic bias across age and sex cohorts, and compliance with medical device software regulations in the United States, European Union, and other major markets.

Key Regional Insights Across Urinary Incontinence Device Demand

Asia-Pacific is a high-priority opportunity due to large patient populations, rapid aging in Japan, South Korea, China, and Australia, and expanding middle-class access to specialty care. Regional demand is also supported by rising awareness of pelvic floor disorders, growth in private hospitals, and broader use of home healthcare models in urban centers. North America remains a leading innovation and reimbursement market, supported by high urology procedure volumes, advanced home healthcare infrastructure, established medical device regulatory pathways, and strong adoption of digital health tools. Europe benefits from broad clinical guidelines, public healthcare purchasing, continence nurse services, and structured care pathways, although country-level reimbursement variation continues to shape access to advanced urinary incontinence devices.

Latin America is advancing through private hospital networks, growing awareness of pelvic health, and rising demand in Brazil and Mexico, while affordability, public reimbursement gaps, and uneven specialist access remain constraints. The Middle East is supported by hospital modernization, medical tourism, investment in specialty care, and strong procurement capacity across Gulf economies. Africa presents a longer-term access opportunity, where adoption depends on public health capacity, trained clinicians, distribution networks, patient education, and affordability-focused product strategies that address both urban hospitals and underserved community settings.

Key Group Insights Shaping Market Access and Adoption

ASEAN markets are increasingly relevant as urban healthcare systems expand and aging accelerates in Singapore, Thailand, and Vietnam, creating demand for affordable, discreet continence devices and outpatient urology services. The GCC is shaped by high healthcare investment, modern hospital infrastructure, and demand for premium imported technologies, with Saudi Arabia and the United Arab Emirates serving as key entry points for advanced urology, rehabilitation, and women's health services. The European Union is a critical regulatory and procurement arena because Medical Device Regulation requirements elevate clinical evidence, post-market surveillance, traceability, and manufacturer quality systems.

BRICS markets combine scale with complexity: China, India, and Brazil offer large untreated patient populations and expanding specialty-care access, while Russia and South Africa require tailored distribution, localization, and reimbursement strategies. G7 countries remain central to premium innovation, clinical trials, reimbursement benchmarking, home-care adoption, and early uptake of digital and implantable solutions. NATO markets overlap heavily with North America and Europe, where defense and veteran health systems may increase attention to post-surgical, neurologic, mobility-related, and rehabilitation-linked continence care.

Key Country Insights for Market Prioritization

The United States is the most influential market for urinary incontinence devices due to high healthcare spending, FDA-regulated innovation, Medicare and private payer influence, and strong urology and urogynecology networks. Canada offers stable demand through aging demographics, publicly funded care, and established continence services, while Mexico is driven by private healthcare growth, medical tourism, and expanding access to specialty treatment. Brazil is Latin America's largest opportunity, supported by urban hospital systems, a large aging population, and rising awareness of women's health, pelvic floor care, and prostate-care outcomes.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature but diverse purchasing environments, with Germany and France emphasizing clinical evidence and reimbursement rigor, and the United Kingdom focusing on NHS cost-effectiveness, procurement efficiency, and care pathway standardization. Italy and Spain continue to reflect strong demand from aging populations and public healthcare systems, while Russia remains a selective opportunity shaped by local procurement, regulatory alignment, and supply-chain considerations. In Asia-Pacific, China and India offer scale and underpenetrated demand linked to aging, urbanization, and improving specialty access; Japan and South Korea present advanced aging-driven markets with high expectations for quality and usability; and Australia provides a well-regulated setting with strong continence-care awareness, reimbursement structures, and home-care adoption.

Actionable Recommendations for Urinary Incontinence Device Leaders

Industry leaders should prioritize clinically validated differentiation. Products that demonstrate reduced infection risk, improved adherence, fewer leakage episodes, lower caregiver time, improved sleep quality, and better patient-reported quality of life will be better positioned for payer acceptance and provider adoption. Companies should invest in real-world evidence, post-market surveillance, human-factors testing, and outcomes research that reflects women, older adults, post-prostatectomy patients, neurologic populations, and long-term care residents.

Commercial strategies should align product portfolios with care settings. Acute-care systems need safe perioperative and catheter-management solutions, outpatient clinics need minimally invasive and durable interventions, and home-care providers need easy-to-use external and connected devices. Manufacturers should strengthen reimbursement expertise, regional distribution partnerships, clinician training programs, patient education, and digital compliance frameworks while designing products for affordability, dignity, skin safety, and ease of use.

Research Methodology Based on Verified Healthcare Evidence

This executive summary applies a structured secondary research methodology grounded in verified public sources, regulatory frameworks, clinical guidelines, demographic datasets, and healthcare market indicators. Sources considered include public health agencies, medical device regulators, urology and continence societies, payer documentation, hospital procurement references, peer-reviewed clinical literature, and macroeconomic and aging-population data from recognized statistical organizations.

The analysis triangulates demand drivers, care pathway shifts, technology adoption, reimbursement dynamics, regional healthcare capacity, regulatory requirements, and competitive innovation trends. Insights are presented qualitatively to avoid unsupported market-size claims and to maintain alignment with verified evidence available across jurisdictions. Regional, group, and country perspectives were integrated into narrative sections to improve relevance while preserving executive readability.

Conclusion: Evidence-Led Growth in Continence Device Innovation

The urinary incontinence device market is moving beyond basic containment toward clinically integrated, patient-centered, and data-enabled continence care. Aging demographics, higher awareness of pelvic health, post-surgical continence needs, neurologic disease burden, and pressure to reduce healthcare-associated complications are expanding demand across hospitals, outpatient clinics, long-term care, and home settings.

Winning companies will combine engineering quality with clinical evidence, reimbursement readiness, regulatory discipline, and empathetic design. As AI, connected monitoring, external collection systems, and minimally invasive technologies mature, the market will reward solutions that improve quality of life, reduce total care burden, and support measurable outcomes across diverse patient populations and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary Incontinence Device Market, by Device Type

• 7.1. External Devices
  • 7.1.1. Catheters
  • 7.1.2. Collectors & Drip Collectors
  • 7.1.3. Penile Clamps
• 7.2. Internal Devices
  • 7.2.1. Artificial Urinary Sphincters
  • 7.2.2. Pessaries
  • 7.2.3. Sacral Nerve Stimulation Devices
  • 7.2.4. Urethral Inserts
  • 7.2.5. Vaginal Slings

8. Urinary Incontinence Device Market, by Material

• 8.1. Latex
• 8.2. Polymer-based Materials
• 8.3. Silicone

9. Urinary Incontinence Device Market, by Technology

• 9.1. Electrical Stimulation Devices
• 9.2. Mechanical Devices
• 9.3. Surgical Implants

10. Urinary Incontinence Device Market, by Gender

• 10.1. Female
• 10.2. Male

11. Urinary Incontinence Device Market, by Form

• 11.1. Disposable
• 11.2. Reusable

12. Urinary Incontinence Device Market, by Age Group

• 12.1. Adult
• 12.2. Pediatrics

13. Urinary Incontinence Device Market, by Application

• 13.1. Functional Incontinence
• 13.2. Overflow Incontinence
• 13.3. Stress Incontinence
• 13.4. Urge Continence

14. Urinary Incontinence Device Market, by End User

• 14.1. Ambulatory Surgical Centers
• 14.2. Homecare Settings
• 14.3. Hospitals & Clinics
• 14.4. Long-Term Care Facilities

15. Urinary Incontinence Device Market, by Distribution Channel

• 15.1. Offline
• 15.2. Online

16. Urinary Incontinence Device Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Urinary Incontinence Device Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Urinary Incontinence Device Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. Aeroflow Inc.
• 20.2. Amber Therapeutics
• 20.3. Attends Healthcare Products, Inc. by Domtar Corporation
• 20.4. Avanos Medical, Inc.
• 20.5. Avation Medical
• 20.6. B. Braun SE
• 20.7. Becton, Dickinson and Company
• 20.8. BioDerm, Inc.
• 20.9. Boston Scientific Corporation
• 20.10. Caldera Medical
• 20.11. Coloplast A/S
• 20.12. Contipi Medical
• 20.13. ConvaTec Group PLC
• 20.14. Essity AB
• 20.15. Hollister Incorporated
• 20.16. Johnson & Johnson Services Inc.
• 20.17. Kimberly-Clark Corporation
• 20.18. Laborie
• 20.19. Life360 Innovation, Inc.
• 20.20. Medtronic PLC
• 20.21. Olympus Corporation
• 20.22. Ontex Group NV
• 20.23. Pelvital USA Inc.
• 20.24. PROMEDON GmbH
• 20.25. Styker Corporation
• 20.26. Teleflex Incorporated
• 20.27. Watkins-Conti Products, Inc.